GO:0062044 negative regulation of cardiac epithelial to mesenchymal transition: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0062044 describes any process that stops or decreases the rate, frequency or extent of cardiac epithelial to mesenchymal transition (EMT), a transition in which cardiac epithelial cells lose polarity, dissolve junctions, degrade basement membrane and become migratory mesenchymal cells.
• Cardiac EMT is a normal developmental program required for valve formation and cushion morphogenesis, but its inappropriate reactivation contributes to fibrosis and valve disease.
• Negative regulation of cardiac EMT is achieved by secreted BMP antagonists, microRNAs, junctional proteins such as p120-catenin, and extracellular matrix components such as hyaluronan.
• miR-194-3p restrains EMT in embryonic epicardial cells through p120/beta-catenin signaling, illustrating post-transcriptional control of this process.
• miRNA-146a-5p inhibits hypoxia-induced endothelial-to-mesenchymal transition and myocardial fibrosis, showing that related negative-regulatory mechanisms protect the heart.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of candidate negative regulators of cardiac EMT in relevant cell and animal systems.
Description
GO:0062044, negative regulation of cardiac epithelial to mesenchymal transition, is a biological process term that captures the braking mechanisms which restrain cardiac EMT. Cardiac EMT is a developmental transition in which epithelial cells of the heart lose apical-basal polarity, sever intercellular adhesive junctions, degrade basement membrane components and become migratory mesenchymal cells. This process is essential for normal valve formation and cardiac cushion morphogenesis, but it must be tightly limited in time and space. The term GO:0062044 therefore describes the cellular and molecular events that stop or decrease the rate, frequency or extent of this transition. Understanding negative regulation of cardiac EMT matters because excessive or misplaced EMT underlies fibrotic remodeling and valve pathology, and because the same signaling nodes are attractive targets for therapeutic intervention. Researchers studying cardiac development, valve disease and fibrosis need reliable models to test whether a candidate gene restrains or promotes this transition.
negative regulation of cardiac epithelial to mesenchymal transition At A Glance
| GO ID | GO:0062044 |
|---|---|
| GO term | negative regulation of cardiac epithelial to mesenchymal transition |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops or decreases the rate, frequency or extent of cardiac epithelial to mesenchymal transition |
| Process context | Cardiac development, valve formation, cushion morphogenesis and fibrotic remodeling |
| Cellular events affected | Loss of apical/basolateral polarity, severing of intercellular adhesive junctions, basement membrane degradation and acquisition of a migratory mesenchymal phenotype |
| Representative regulators | Secreted BMP antagonists, microRNAs such as miR-194-3p and miRNA-146a-5p, junctional proteins such as p120-catenin, and extracellular matrix components such as hyaluronan |
| Research relevance | Provides a framework for testing causal roles of candidate genes in cardiac EMT restraint using CRISPR models |
What Is GO:0062044?
In plain terms, GO:0062044 is the set of processes that put the brakes on cardiac EMT. According to the QuickGO definition, it refers to any process that stops or decreases the rate, frequency or extent of cardiac epithelial to mesenchymal transition, a transition where a cardiac epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. This is a biological_process term, and it has no listed synonyms. It is distinct from the positive regulation of cardiac EMT and from the core EMT process itself, because it specifically covers inhibitory inputs that limit the transition.
Why Is negative regulation of cardiac epithelial to mesenchymal transition Important in Cell Biology?
Negative regulation of cardiac EMT is important because cardiac EMT is a powerful developmental program that must be switched off at the right time and place. When this braking system fails, epithelial cells can inappropriately acquire a migratory mesenchymal phenotype, contributing to valve malformation and fibrotic remodeling. Conversely, understanding the negative regulators offers a route to therapeutic strategies that reinforce these brakes in disease. The process also serves as a paradigm for how secreted antagonists, microRNAs and junctional complexes cooperate to control a complex morphogenetic transition.
• Cardiac EMT is required for normal valve formation and cardiac cushion morphogenesis, so its negative regulation ensures proper timing and location of the transition.
• Loss of negative regulation can lead to excessive mesenchymal cell production and valve abnormalities.
• MicroRNAs such as miR-194-3p act as negative regulators of EMT in embryonic epicardial cells, linking post-transcriptional control to cardiac development.
• miRNA-146a-5p inhibits hypoxia-induced endothelial-to-mesenchymal transition and myocardial fibrosis, showing that negative regulation protects against fibrotic disease.
• Secreted BMP antagonists and extracellular matrix components such as hyaluronan modulate the extent of cardiac EMT during valve formation.
• Junctional proteins such as p120-catenin help maintain the epithelial state and are targets of negative regulatory pathways.
• The process is relevant to chronic pulmonary and vascular diseases in which endothelial-to-mesenchymal transition contributes to pathogenesis.
• Inflammation-mediated endothelial-to-mesenchymal transition can be modulated by small molecules, suggesting pharmacological control of related transitions.
• DLL4 signaling influences partial endothelial-to-mesenchymal transition at atherosclerosis-prone regions, highlighting context-dependent regulation of related transitions.
• Mechanically activated snai1b coordinates myocardial delamination for trabeculation, illustrating how mechanical cues intersect with EMT-like programs.
What Happens During negative regulation of cardiac epithelial to mesenchymal transition?
Maintenance of epithelial polarity and junctions
In simple terms: The cell keeps its top-bottom orientation and stays glued to its neighbors.
Negative regulation of cardiac EMT begins with preserving the epithelial architecture. Cardiac epithelial cells normally have apical/basolateral polarity and intact intercellular adhesive junctions. Junctional proteins such as p120-catenin are central to this maintenance, and pathways that stabilize p120/beta-catenin signaling restrain the transition. When these junctional complexes are protected, the cell cannot easily detach and become migratory, so the EMT program is held in check.
Secreted antagonists of BMP signaling
In simple terms: Brake molecules outside the cell block the signals that would push cells to become mesenchymal.
Secreted BMP antagonists act as extracellular brakes on cardiac EMT. BMPER is a BMP-binding protein that promotes epithelial-mesenchymal transition in the developing cardiac cushions, and its modulation illustrates how the balance of BMP agonists and antagonists controls the transition. Negative regulation of cardiac EMT therefore involves secreted factors that limit BMP-driven mesenchymal conversion during cushion morphogenesis.
MicroRNA-mediated post-transcriptional control
In simple terms: Small RNA molecules reduce the production of proteins that drive the transition.
MicroRNAs provide a powerful layer of negative regulation. miR-194-3p regulates epithelial-mesenchymal transition in embryonic epicardial cells via p120/beta-catenin signaling, acting as a restraint on the transition. Similarly, miRNA-146a-5p inhibits hypoxia-induced endothelial-to-mesenchymal transition and myocardial fibrosis, demonstrating that microRNA-based negative regulation can protect the heart from fibrotic remodeling. These examples show that post-transcriptional silencing of EMT-promoting transcripts is a core mechanism of GO:0062044.
Extracellular matrix and hyaluronan control
In simple terms: The material around cells can either encourage or block the transition.
The extracellular matrix is an active participant in negative regulation. Hyaluronan is a critical regulator of endothelial-to-mesenchymal transition during cardiac valve formation, and its abundance and organization influence whether cells undergo the transition. By modulating matrix composition and availability, the tissue environment can decrease the rate and extent of cardiac EMT, contributing to the negative regulation captured by GO:0062044.
Inflammatory and mechanical modulation
In simple terms: Inflammation and physical forces can dial the transition up or down.
Inflammatory signals and mechanical cues intersect with negative regulation of cardiac EMT. Inflammation-mediated endothelial-to-mesenchymal transition can be modulated by compounds such as echinochrome A, which improves myocardial dysfunction. DLL4 promotes partial endothelial-to-mesenchymal transition at atherosclerosis-prone regions, showing that Notch-related signaling can influence the extent of the transition. Mechanically activated snai1b coordinates myocardial delamination for trabeculation, indicating that mechanical forces are integrated into EMT-like programs. Together, these inputs can either oppose or reinforce the negative regulation described by GO:0062044.
Key Genes Involved in GO:0062044 negative regulation of cardiac epithelial to mesenchymal transition
The following genes and proteins have been implicated in cardiac EMT and related transitions, and they represent candidate nodes for studying negative regulation of cardiac EMT.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BMPER | BMP-binding protein that promotes EMT in developing cardiac cushions | Candidate modulator of the balance between pro-EMT and anti-EMT signals in cushion morphogenesis |
| miR-194-3p | MicroRNA that regulates EMT in embryonic epicardial cells via p120/beta-catenin signaling | Potential negative regulator of cardiac EMT through post-transcriptional control |
| miRNA-146a-5p | MicroRNA that inhibits hypoxia-induced endothelial-to-mesenchymal transition and myocardial fibrosis | Model for microRNA-based negative regulation protecting against cardiac fibrosis |
| p120-catenin | Junctional protein that maintains epithelial adhesion and is targeted by miR-194-3p signaling | Central node for preserving epithelial state and restraining EMT |
| Hyaluronan | Extracellular matrix component critical for endothelial-to-mesenchymal transition during cardiac valve formation | Matrix-based regulator of the extent of cardiac EMT |
| DLL4 | Notch ligand that promotes partial endothelial-to-mesenchymal transition at atherosclerosis-prone regions | Context-dependent regulator of related transitions in vascular disease |
| snai1b | Mechanically activated transcription factor coordinating myocardial delamination for trabeculation | Links mechanical cues to EMT-like programs in the heart |
| Echinochrome A | Small molecule that modulates inflammation-mediated endothelial-to-mesenchymal transition | Pharmacological tool for studying negative regulation of related transitions |
| BMP signaling components | Pathway that drives EMT in cardiac cushions and is antagonized by BMPER | Core pathway whose inhibition contributes to negative regulation |
| Beta-catenin | Signaling molecule interacting with p120-catenin in epicardial EMT regulation | Effector node in microRNA-mediated negative regulation |
| Notch pathway components | Signaling axis influencing endothelial-to-mesenchymal transition | Candidate modulators of transition extent in vascular and cardiac contexts |
| Inflammatory cytokines | Signals that promote endothelial-to-mesenchymal transition and can be modulated pharmacologically | Targets for anti-fibrotic and anti-EMT strategies |
| Hypoxia-responsive factors | Mediators of hypoxia-induced endothelial-to-mesenchymal transition | Upstream inducers whose inhibition supports negative regulation |
| Extracellular matrix remodeling enzymes | Enzymes that alter matrix composition and influence EMT | Potential modifiers of hyaluronan-dependent regulation |
| Trabeculation regulators | Genes controlling myocardial delamination and trabeculation | Model for mechanical control of EMT-like processes |
| Vascular disease-associated genes | Genes linked to chronic pulmonary and vascular diseases involving endothelial-to-mesenchymal transition | Broader context for negative regulation of related transitions |
How Is negative regulation of cardiac epithelial to mesenchymal transition Regulated?
Negative regulation of cardiac EMT is itself regulated at multiple levels. Secreted BMP antagonists such as BMPER modulate the availability of pro-EMT BMP signals in the developing cardiac cushions. MicroRNAs including miR-194-3p and miRNA-146a-5p provide post-transcriptional control by targeting components of the EMT machinery, such as p120/beta-catenin signaling and hypoxia-induced pathways. Extracellular matrix components, notably hyaluronan, regulate the physical and biochemical environment that permits or restrains the transition during valve formation. Inflammatory and mechanical inputs can also shift the balance, as shown by modulation of inflammation-mediated endothelial-to-mesenchymal transition and by mechanically activated snai1b during trabeculation. Together, these layers ensure that cardiac EMT occurs only when and where it is needed.
negative regulation of cardiac epithelial to mesenchymal transition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| miRNA-146a-5p | Hypoxia-induced myocardial fibrosis | Hypoxia-treated cardiac endothelial cells with miRNA-146a-5p overexpression or knockout |
| miR-194-3p | Embryonic epicardial EMT and cardiac development | Embryonic epicardial cell cultures with miR-194-3p mimic or inhibitor |
| BMPER | Cardiac cushion morphogenesis and valve development | Developing cardiac cushion explants with BMPER loss- or gain-of-function |
| Hyaluronan | Cardiac valve formation | Valve-forming region explants with hyaluronan synthesis or degradation modulation |
| DLL4 | Atherosclerosis-prone vascular regions | Arterial endothelial cells under flow with DLL4 perturbation |
Cardiac valve disease and developmental defects
Cardiac EMT is essential for valve formation, and its negative regulation ensures that cushion morphogenesis proceeds correctly. Hyaluronan is a critical regulator of endothelial-to-mesenchymal transition during cardiac valve formation, and perturbations in this regulation can lead to valve abnormalities. BMPER promotes EMT in the developing cardiac cushions, and an imbalance between pro-EMT and anti-EMT signals may contribute to congenital valve defects. Thus, genes that mediate GO:0062044 are candidate modifiers of valve disease risk.
Myocardial fibrosis
Excessive endothelial-to-mesenchymal transition contributes to myocardial fibrosis. miRNA-146a-5p inhibits hypoxia-induced endothelial-to-mesenchymal transition and myocardial fibrosis, demonstrating that reinforcing negative regulation can be protective. Inflammation-mediated endothelial-to-mesenchymal transition can also be modulated to improve myocardial dysfunction, suggesting that anti-inflammatory strategies may act in part by restoring negative regulation. These findings position GO:0062044 as a therapeutic axis in fibrotic heart disease.
Chronic pulmonary and vascular diseases
Endothelial-to-mesenchymal transition is implicated in the pathogenesis of chronic pulmonary and vascular diseases, where it contributes to vascular remodeling. DLL4 promotes partial endothelial-to-mesenchymal transition at atherosclerosis-prone regions of arteries, illustrating how local signals can drive the transition in disease-prone vasculature. Understanding the negative regulators of these related transitions may inform therapies that limit pathological remodeling.
From negative regulation of cardiac epithelial to mesenchymal transition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required to restrain cardiac EMT? | CRISPR knockout in cardiac epithelial or endothelial cells followed by EMT induction assays |
| Does a specific phosphorylation site control the anti-EMT function? | CRISPR point mutation knock-in of the phospho-site in the endogenous locus |
| Does a disease-associated variant impair negative regulation? | CRISPR knock-in of the patient variant and comparison with wild-type isogenic controls |
| Where and when is the regulator expressed during heart development? | Tagged knock-in with fluorescent or epitope tag and imaging of developing hearts |
| Can overexpression of a negative regulator block fibrosis? | CRISPR overexpression or lentiviral overexpression in hypoxia-induced fibrosis models |
| Which genes cooperate in the negative regulation network? | CRISPR library screening in cardiac EMT reporter cell lines |
How to Study the negative regulation of cardiac epithelial to mesenchymal transition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes during EMT and its inhibition | Identifying signatures of negative regulation in cardiac cells |
| MicroRNA mimic/inhibitor assays | Functional impact of microRNAs on EMT markers | Testing miR-194-3p or miRNA-146a-5p as negative regulators |
| Co-immunoprecipitation | Protein-protein interactions in junctional complexes | Assessing p120-catenin/beta-catenin complex integrity |
| Immunofluorescence | Localization of junctional and polarity proteins | Visualizing epithelial architecture in cardiac cells |
| Cardiac cushion explant culture | EMT occurrence in a native tissue context | Studying BMPER and hyaluronan effects on cushion morphogenesis |
| Lineage tracing | Fate of cells undergoing EMT in vivo | Tracking mesenchymal derivatives during valve formation |
| Hypoxia-induced fibrosis model | Endothelial-to-mesenchymal transition under pathological stress | Testing protective microRNAs against myocardial fibrosis |
| Flow-based vascular assays | Partial endothelial-to-mesenchymal transition under shear stress | Evaluating DLL4-dependent regulation in arteries |
Transcriptomic profiling of EMT states
RNA sequencing can compare epithelial and mesenchymal states after perturbation of candidate negative regulators. This approach identifies gene expression signatures associated with loss of polarity, junction disassembly and acquisition of migratory programs. In the context of GO:0062044, RNA-seq helps define which transcripts are suppressed when negative regulation is active and which are de-repressed upon its loss.
MicroRNA and target validation
Because microRNAs such as miR-194-3p and miRNA-146a-5p act as negative regulators, methods that measure microRNA abundance and target engagement are essential. Reporter assays, mimic and inhibitor experiments, and target-site mutagenesis can establish direct regulation of EMT-related transcripts.
Protein interaction and junctional complex analysis
Co-immunoprecipitation, proximity ligation and immunofluorescence can assess the integrity of junctional complexes involving p120-catenin and beta-catenin. These methods reveal whether a candidate negative regulator stabilizes epithelial junctions or promotes their disassembly.
In vivo cardiac morphogenesis assays
Whole-mount imaging, lineage tracing and explant culture of cardiac cushions or valve-forming regions allow direct observation of EMT in a developmental context. Such assays are critical for linking molecular negative regulators to the morphogenetic events described by GO:0062044.
How CRISPR Can Be Used to Study GO:0062044 negative regulation of cardiac epithelial to mesenchymal transition
Knockout
CRISPR knockout of a candidate negative regulator can test whether the gene is required to restrain cardiac EMT. Loss-of-function models may show increased mesenchymal marker expression, loss of junctional integrity or enhanced migration in cardiac epithelial cells. Such experiments provide causal evidence that the gene contributes to GO:0062044.
Point Mutation
Point mutation knock-in allows precise interrogation of phosphorylation sites, catalytic residues or interaction interfaces within a negative regulator. By introducing a single amino acid change in the endogenous locus, researchers can determine whether a specific modification is necessary for the anti-EMT function, as has been explored for signaling nodes involving p120-catenin and beta-catenin.
Knock-in
Knock-in of reporters, tags or disease-associated variants enables visualization and functional analysis of negative regulators in their native context. Tagged knock-in lines can reveal expression dynamics during cardiac cushion morphogenesis, while variant knock-in models can test whether patient alleles impair the braking of cardiac EMT.
Overexpression
CRISPR-mediated overexpression or lentiviral overexpression of a candidate negative regulator can test whether increasing its dosage is sufficient to block EMT. This is particularly relevant for microRNAs such as miRNA-146a-5p, whose overexpression inhibits hypoxia-induced endothelial-to-mesenchymal transition and myocardial fibrosis. Overexpression models can also validate secreted antagonists and matrix components that restrain the transition.
How EDITGENE Supports negative regulation of cardiac epithelial to mesenchymal transition Research
Researchers studying negative regulation of cardiac epithelial to mesenchymal transition-related genes often need to determine whether a candidate gene is causally involved in restraining the transition or is merely correlated with it. Establishing causality requires precise genetic models that can remove, modify, tag or overexpress the gene of interest in relevant cardiac cell types. EDITGENE provides a comprehensive suite of CRISPR-based services designed to support exactly these experimental needs.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac epithelial to mesenchymal transition research.
Frequently Asked Questions About negative regulation of cardiac epithelial to mesenchymal transition
What is GO:0062044?
GO:0062044 is the Gene Ontology term for negative regulation of cardiac epithelial to mesenchymal transition. It describes any process that stops or decreases the rate, frequency or extent of cardiac EMT, in which cardiac epithelial cells lose polarity, dissolve junctions, degrade basement membrane and become migratory mesenchymal cells.
What is cardiac epithelial to mesenchymal transition?
Cardiac EMT is a developmental transition where cardiac epithelial cells lose apical/basolateral polarity, sever intercellular adhesive junctions, degrade basement membrane components and become migratory mesenchymal cells. It is essential for valve formation and cushion morphogenesis.
What genes are involved in negative regulation of cardiac EMT?
Genes and factors implicated in restraining cardiac EMT include miR-194-3p, miRNA-146a-5p, p120-catenin, BMPER, hyaluronan-related matrix components and DLL4, among others.
How is cardiac EMT negatively regulated?
Negative regulation occurs through maintenance of epithelial junctions, secreted BMP antagonists, microRNA-mediated silencing of EMT-promoting transcripts, extracellular matrix components such as hyaluronan, and modulation by inflammatory and mechanical signals.
Why is negative regulation of cardiac EMT important?
It ensures that cardiac EMT occurs only at the right time and place during development. Loss of this braking system can contribute to valve abnormalities and fibrotic remodeling, making these regulators attractive therapeutic targets.
Which microRNAs inhibit cardiac EMT?
miR-194-3p regulates EMT in embryonic epicardial cells via p120/beta-catenin signaling, and miRNA-146a-5p inhibits hypoxia-induced endothelial-to-mesenchymal transition and myocardial fibrosis.
What role does hyaluronan play in cardiac valve formation?
Hyaluronan is a critical regulator of endothelial-to-mesenchymal transition during cardiac valve formation, influencing the extent of the transition in the developing heart.
How can CRISPR be used to study negative regulation of cardiac EMT?
CRISPR knockout can test whether a gene is required to restrain EMT, point mutation can interrogate specific residues, knock-in can tag or model variants, and overexpression can test sufficiency of a negative regulator.
Is endothelial-to-mesenchymal transition related to cardiac EMT?
Yes, endothelial-to-mesenchymal transition is a related process that contributes to cardiac valve formation and to vascular and pulmonary diseases, and many regulatory principles are shared.
What diseases are linked to dysregulated cardiac EMT?
Dysregulated cardiac EMT and related transitions are linked to cardiac valve defects, myocardial fibrosis, and chronic pulmonary and vascular diseases.
Conclusion
GO:0062044, negative regulation of cardiac epithelial to mesenchymal transition, defines the braking mechanisms that limit a powerful developmental program. These mechanisms include junctional maintenance, secreted BMP antagonists, microRNA-mediated silencing, extracellular matrix control and modulation by inflammatory and mechanical cues. Because loss of this negative regulation can contribute to valve abnormalities and fibrotic disease, the genes and pathways that mediate it are important research targets. CRISPR-based knockout, point mutation, knock-in and overexpression models provide the causal evidence needed to move from correlation to mechanism in this field.
References
- 1. Song BW et al.. 2022. Regulation of Inflammation-Mediated Endothelial to Mesenchymal Transition with Echinochrome a for Improving Myocardial Dysfunction.. Mar Drugs 20(12) PMID: 36547903
- 2. Li X et al.. 2023. DLL4 promotes partial endothelial-to-mesenchymal transition at atherosclerosis-prone regions of arteries.. Vascul Pharmacol 150:107178 PMID: 37137436
- 3. Lagendijk AK et al.. 2013. Hyaluronan: a critical regulator of endothelial-to-mesenchymal transition during cardiac valve formation.. Trends Cardiovasc Med 23(5):135-42 PMID: 23295082
- 4. Dyer L et al.. 2015. BMPER Promotes Epithelial-Mesenchymal Transition in the Developing Cardiac Cushions.. PLoS One 10(9):e0139209 PMID: 26418455
- 5. Wang J et al.. 2025. Mechanically activated snai1b coordinates the initiation of myocardial delamination for trabeculation.. Nat Commun 16(1):8363 PMID: 40993149
- 6. Lu X et al.. 2019. Endothelial-to-mesenchymal transition: Pathogenesis and therapeutic targets for chronic pulmonary and vascular diseases.. Biochem Pharmacol 168:100-107 PMID: 31251941
- 7. Xiong T et al.. 2024. miR-194-3p regulates epithelial-mesenchymal transition in embryonic epicardial cells via p120/β-catenin signaling.. Acta Biochim Biophys Sin (Shanghai) 56(5):717-729 PMID: 38676398
- 8. Wang Y et al.. 2024. miRNA-146a-5p Inhibits Hypoxia-Induced Myocardial Fibrosis Through EndMT.. Cardiovasc Toxicol 24(2):133-145 PMID: 38180639
